Abstract C020: First-in-human phase 1/1b trial of the first-in-class bi-steric mTORC1-selective inhibitor RMC-5552 in patients with advanced solid tumorsAlison M. Schram, Howard A. Burris, Eric B. Haura et al.|Molecular Cancer Therapeutics|2023Cited by 8